ERBB2 and gastric adenocarcinoma: Upcoming trials to evaluate the value of trastuzumab in gastric cancer are ML25189, a phase II study, planning to recruit 45 patients suffering from resectable and HER2 positive gastric adenocarcinoma or gastro-esophageal junction cancer (type I–III) [32] and the US Radiation Therapy Oncology Group (RTOG)-1010 accrues for a larger, phase III trial with a planned number of 480 patients [33].